Indicative listing context
Neuralink Stock Price (Pre-IPO)
Neuralink is private. The brain-computer interface company has never listed publicly, so there is no official Neuralink stock price. Segmara tracks an indicative pre-IPO reference mark for Neuralink, shown live in the data summary below, with a free email tracker.
Get free Neuralink trackerThis page is not an offer, allocation, recommendation, investment application, payment workflow, brokerage instruction, or issuer-affiliated workflow.
Limited intake
Start with name and email only.
Use the inquiry form to open one account workspace. No public ID upload, payment card, bank detail, wallet address, or document upload is requested on this step.
Request review with name + emailNeuralink round data and risk-adjusted context
Neuralink is a high-interest private company, but round analysis must account for clinical, regulatory, and long-duration development risk.
Official June 2025 raise
Reported pre-money valuation around the Series E
Neurotechnology timelines are not public-software timelines
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /neuralink-stock-price | Stable URL path for AI and search extraction. |
| Article title | Neuralink Stock Price (Pre-IPO) | Main page topic. |
| Attached public sources | 4 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 51 | Live private-company listings in the public catalogue. |
| Priced listings | 38 | Catalogue listings with visible indicative or direct marks. |
| Request-quote listings | 13 | Catalogue listings where a public price is intentionally not invented. |
| Company | Neuralink | Named company covered by this buying guide. |
| Symbol label | NEUR | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Biotechnology | Catalogue sector used for comparison and internal linking. |
| Listing structure | Indicative | How the listing is categorized on Segmara. |
| Segmara mark | $75.62/sh | Visible listing mark or request-quote state. |
| Sector peer count | 1 | Number of live Segmara listings in Biotechnology. |
| Structure peer count | 9 | Number of live Segmara listings categorized as Indicative. |
| Price rank | 21 of 38 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 47th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $91.25 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | -17% | Difference between this listing mark and the catalogue median mark. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 47 / 100 | $75.62/sh ranks 21 of 38 priced listings |
| Source depth | 68 / 100 | 4 source links |
| Sector peer signal | 42 / 100 | 1 Biotechnology listing(s) |
| Structure specificity | 88 / 100 | Indicative |
Structured data extract
{
"route": "/neuralink-stock-price",
"title": "Neuralink Stock Price (Pre-IPO)",
"company": "Neuralink",
"facts": [
{
"metric": "Canonical route",
"value": "/neuralink-stock-price",
"context": "Stable URL path for AI and search extraction."
},
{
"metric": "Article title",
"value": "Neuralink Stock Price (Pre-IPO)",
"context": "Main page topic."
},
{
"metric": "Attached public sources",
"value": "4",
"context": "Number of citation links rendered at the bottom of the article."
},
{
"metric": "Segmara listed companies",
"value": "51",
"context": "Live private-company listings in the public catalogue."
},
{
"metric": "Priced listings",
"value": "38",
"context": "Catalogue listings with visible indicative or direct marks."
},
{
"metric": "Request-quote listings",
"value": "13",
"context": "Catalogue listings where a public price is intentionally not invented."
},
{
"metric": "Company",
"value": "Neuralink",
"context": "Named company covered by this buying guide."
},
{
"metric": "Symbol label",
"value": "NEUR",
"context": "Segmara display symbol; not a public stock ticker unless separately stated."
},
{
"metric": "Sector",
"value": "Biotechnology",
"context": "Catalogue sector used for comparison and internal linking."
},
{
"metric": "Listing structure",
"value": "Indicative",
"context": "How the listing is categorized on Segmara."
},
{
"metric": "Segmara mark",
"value": "$75.62/sh",
"context": "Visible listing mark or request-quote state."
},
{
"metric": "Sector peer count",
"value": "1",
"context": "Number of live Segmara listings in Biotechnology."
},
{
"metric": "Structure peer count",
"value": "9",
"context": "Number of live Segmara listings categorized as Indicative."
},
{
"metric": "Price rank",
"value": "21 of 38",
"context": "Ranked highest-to-lowest among Segmara listings with visible marks."
},
{
"metric": "Price percentile",
"value": "47th",
"context": "Percentile among visible Segmara catalogue marks."
},
{
"metric": "Catalogue median mark",
"value": "$91.25",
"context": "Median visible mark across priced Segmara listings."
},
{
"metric": "Premium/discount to median",
"value": "-17%",
"context": "Difference between this listing mark and the catalogue median mark."
}
],
"chart_points": [
{
"metric": "Listing price percentile",
"score_0_to_100": 47,
"context": "$75.62/sh ranks 21 of 38 priced listings"
},
{
"metric": "Source depth",
"score_0_to_100": 68,
"context": "4 source links"
},
{
"metric": "Sector peer signal",
"score_0_to_100": 42,
"context": "1 Biotechnology listing(s)"
},
{
"metric": "Structure specificity",
"score_0_to_100": 88,
"context": "Indicative"
}
]
}
Analytical lens
Search intent
The search behind 'Neuralink Stock Price (Pre-IPO)' is an access-intent query. People want to know where they can start interest in Neuralink private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover biotechnology categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
How access works
- The indicative mark, valuation context, and sector percentile render live in the data summary below.
- Compare Neuralink with sector peers in the catalogue, then read the full access guide.
- Track the indicative price free by email. No card, no documents, no brokerage account.
Risk notes
- Private-company exposure can be illiquid, transfer-restricted, and hard to value.
- Indicative marks and reported valuations are orientation points, not executable quotes.
- Availability of any route can depend on jurisdiction, eligibility, structure, and approval.
What private follow-up needs
- Which name or category do you want reviewed?
- Are you an individual, advisor, family office, institution, or other profile?
- What jurisdiction or country should the review consider?
- Do you already know your accredited investor or qualified purchaser status?
- What time horizon and liquidity constraints matter for you?
- Are you asking about private-company exposure, event-market exposure, or both?
Public source links
Related reviews
Questions
Can I start private-share interest for Neuralink through this page?
Yes. This page can collect limited interest for Neuralink, but it does not create an offer, allocation, subscription, payment instruction, or issuer-affiliated workflow. Final availability, eligibility, documents, and terms remain route-specific.
What is the first step?
Submit a limited share inquiry with the relevant interest, contact details, jurisdiction context, and consent. Any later account, document, or payment step is handled separately in private follow-up.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Neuralink or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
What is Neuralink's stock price today?
Neuralink is private, so there is no official public stock price. Segmara publishes an indicative pre-IPO reference mark, shown in the data summary on this page. It is not a live exchange quote and not an offer to sell.
Is Neuralink publicly traded?
No. Neuralink has not held an IPO and its shares do not trade on any public exchange. Any price you see for Neuralink is an indicative private-market estimate.
What is Neuralink worth right now?
Public reporting tracks Neuralink's valuation through its private funding rounds. Segmara's indicative mark reflects private-market signals and is not a guaranteed value.
Can I buy Neuralink stock before the IPO?
Not through a public exchange, and Segmara does not sell, broker, or arrange purchases of Neuralink shares. You can track Neuralink's indicative price for free with Segmara's email tracker and read how pre-IPO access has historically worked.
How does Segmara calculate its indicative mark?
Segmara aggregates private-market signals such as secondary transactions and funding rounds, refreshed periodically. The mark is indicative only: not a live quote, not investment advice, and no allocation or liquidity is guaranteed.
Next step
Track Neuralink free.
Get the indicative Neuralink price by email. Free, email only. No card, no documents, no brokerage account, and no allocation promise.
Get the free Neuralink tracker